Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extensive-stage small-cell lung cancer.

Alexander Spira1, David S Ettinger

  • 1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21231-1000, USA. alexander.spira@usoncology.com

Seminars in Surgical Oncology
|September 26, 2003
PubMed
Summary

Extensive-stage small-cell lung cancer (ES-SCLC) treatment remains challenging, with limited durable responses and poor survival. Cisplatin-based chemotherapy is the current standard, but new therapeutic strategies are under investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy.

Journal of health economics and outcomes research·2026
Same author

Daraxonrasib in Previously Treated Advanced <i>RAS</i>-Mutated Pancreatic Cancer.

The New England journal of medicine·2026
Same author

Erratum: First-In-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.

Nature communications·2026
Same author

BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial.

Cancer chemotherapy and pharmacology·2026
Same author

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2025

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Oncology

Background:

  • Extensive-stage small-cell lung cancer (ES-SCLC) presents significant therapeutic challenges.
  • Current treatments yield high initial response rates but lack durable remissions and long-term survival.
  • Cisplatin-based combination chemotherapy is the established standard of care for ES-SCLC.

Purpose of the Study:

  • To review recent advancements in the treatment and management of ES-SCLC.
  • To discuss emerging therapeutic strategies and future directions for ES-SCLC.

Main Methods:

  • Literature review of recent clinical trials and research findings.
  • Analysis of current treatment paradigms and their limitations.
  • Exploration of novel therapeutic targets and approaches.

Related Experiment Videos

Main Results:

  • Despite advances, durable responses and improved survival in ES-SCLC remain elusive.
  • Cisplatin-based chemotherapy continues to be the cornerstone of treatment.
  • Ongoing research explores novel agents and combination therapies.

Conclusions:

  • ES-SCLC management requires innovative therapeutic strategies beyond current standards.
  • Future research should focus on improving long-term survival and durable responses.
  • A multi-faceted approach combining novel therapies with established treatments may offer improved outcomes.